New data add to the body of evidence supporting efficacy of omidubicel, Gamida Cell’s lead product candidate, which has a target PDUFA action date with U.S. Food and Drug Administration (FDA) of May 1, 2023
New data for GDA-201, Gamida Cell’s natural killer (NK) cell therapy candidate in ongoing Phase 1/2 study for non-Hodgkin lymphoma, show robust immune system engagement and high cytotoxicity levels
https://finance.yahoo.com/news/data-presented-gamida-cell-omidubicel-173000062.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.